Literature DB >> 22210559

Nitric oxide donors for the treatment of osteoporosis.

Sophie A Jamal1, Celeste J Hamilton.   

Abstract

The number of osteoporotic fractures is increasing worldwide as populations age. An inexpensive and widely available treatment is necessary to alleviate this increase in fractures. Current treatments decrease fractures at trabecular bone sites (spine) but have limited effects at cortical sites (hip, legs, forearm, and upper arm)-the most common sites of osteoporotic fracture. Treatments are also limited by costs, side effects, and lack of availability. Nitric oxide is a novel agent that has the potential to influence cortical bone, is inexpensive, is widely available, and has limited side effects. In this review we evaluate the in vitro and in vivo data which support the concept that nitric oxide is important in bone cell function, review the observational and case-control studies reporting on subjects taking organic nitrates that act as nitric oxide donors, and review the effects of nitrates on bone mineral density measurements and fracture risk.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22210559     DOI: 10.1007/s11914-011-0087-7

Source DB:  PubMed          Journal:  Curr Osteoporos Rep        ISSN: 1544-1873            Impact factor:   5.096


  53 in total

1.  Nitric oxide is a regulator of bone remodelling.

Authors:  H J Chae; R K Park; H T Chung; J S Kang; M S Kim; D Y Choi; B G Bang; H R Kim
Journal:  J Pharm Pharmacol       Date:  1997-09       Impact factor: 3.765

Review 2.  The Michael Mason Prize Essay 1997. Nitric oxide and bone: what a gas!

Authors:  S H Ralston
Journal:  Br J Rheumatol       Date:  1997-08

3.  Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial.

Authors:  Sophie A Jamal; Douglas C Bauer; Kristine E Ensrud; Jane A Cauley; Marc Hochberg; Areef Ishani; Steven R Cummings
Journal:  J Bone Miner Res       Date:  2007-04       Impact factor: 6.741

4.  Pharmacokinetics of nitroglycerin and long-acting nitrate esters.

Authors:  H L Fung
Journal:  Am J Med       Date:  1983-06-27       Impact factor: 4.965

5.  Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.

Authors:  Ego Seeman; Pierre D Delmas; David A Hanley; Deborah Sellmeyer; Angela M Cheung; Elizabeth Shane; Ann Kearns; Thierry Thomas; Steven K Boyd; Stephanie Boutroy; Cesar Bogado; Sharmila Majumdar; Michelle Fan; Cesar Libanati; Jose Zanchetta
Journal:  J Bone Miner Res       Date:  2010-08       Impact factor: 6.741

6.  Inhibition of avian osteoclast bone resorption by monoclonal antibody 121F: a mechanism involving the osteoclast free radical system.

Authors:  P Collin-Osdoby; L Li; L Rothe; F Anderson; D Kirsch; M J Oursler; P Osdoby
Journal:  J Bone Miner Res       Date:  1998-01       Impact factor: 6.741

7.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

Review 8.  Nitric oxide and its role in orthopaedic disease.

Authors:  C H Evans; M Stefanovic-Racic; J Lancaster
Journal:  Clin Orthop Relat Res       Date:  1995-03       Impact factor: 4.176

9.  Isosorbide mononitrate increases bone formation and decreases bone resorption in postmenopausal women: a randomized trial.

Authors:  Sophie A Jamal; Steven R Cummings; Gillian A Hawker
Journal:  J Bone Miner Res       Date:  2004-07-26       Impact factor: 6.741

10.  Bone loss and bone size after menopause.

Authors:  Henrik G Ahlborg; Olof Johnell; Charles H Turner; Gunnar Rannevik; Magnus K Karlsson
Journal:  N Engl J Med       Date:  2003-07-24       Impact factor: 91.245

View more
  5 in total

1.  The Protective and Therapeutic Effect of Exclusive and Combined Treatment with Alpha-ketoglutarate Sodium Salt and Ipriflavone on Bone Loss in Orchidectomized Rats.

Authors:  R P Radzki; M Bieńko; R Filip; S G Pierzynowski
Journal:  J Nutr Health Aging       Date:  2016       Impact factor: 4.075

2.  The influence of disuse on bone microstructure and mechanics assessed by HR-pQCT.

Authors:  Galateia J Kazakia; Willy Tjong; Jasmine A Nirody; Andrew J Burghardt; Julio Carballido-Gamio; Janina M Patsch; Thomas Link; Brian T Feeley; C Benjamin Ma
Journal:  Bone       Date:  2014-03-03       Impact factor: 4.398

3.  Soluble guanylate cyclase as a novel treatment target for osteoporosis.

Authors:  Jisha Joshua; Gerburg K Schwaerzer; Hema Kalyanaraman; Esther Cory; Robert L Sah; Mofei Li; Florin Vaida; Gerry R Boss; Renate B Pilz
Journal:  Endocrinology       Date:  2014-09-04       Impact factor: 4.736

4.  The effect of PDE5 inhibitors on bone and oxidative damage in ovariectomy-induced osteoporosis.

Authors:  Hamit H Alp; Zübeyir Huyut; Serkan Yildirim; Yıldıray Başbugan; Levent Ediz; Mehmet R Şekeroğlu
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-11

Review 5.  Precision Redox: The Key for Antioxidant Pharmacology.

Authors:  Jiao Meng; Zhenyu Lv; Yingmin Zhang; Yuanyuan Wang; Xinhua Qiao; Chuanxin Sun; Yuzhe Chen; Miaomiao Guo; Wensheng Han; Aojun Ye; Ting Xie; Boyu Chu; Chang Shi; Shangpo Yang; Chang Chen
Journal:  Antioxid Redox Signal       Date:  2020-12-02       Impact factor: 8.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.